Cancer Pain Management — Part 3: Opioid Therapy — Selection, Titration, Rotation, and Adverse Effect Management

Opioid Selection and Initiation

General Principles

Strong opioids are the mainstay of treatment for moderate-to-severe cancer pain. There is no single “best” opioid for cancer pain; selection should be individualized based on pain intensity, patient comorbidities, prior opioid exposure, available formulations, renal and hepatic function, potential drug interactions, and cost/availability.¹

Key principles for opioid initiation:

• Start with an immediate-release (IR) formulation for initial dose-finding (titration)
• Begin at the lowest appropriate dose in opioid-naive patients
• Prescribe around-the-clock dosing for persistent pain, with a separate breakthrough (rescue) dose
• Titrate based on analgesic response and tolerability
• Once a stable daily dose is established, consider conversion to an extended-release (ER) formulation with IR rescue doses for breakthrough pain
• Always co-prescribe a prophylactic bowel regimen
• Reassess frequently during titration (every 24–72 hours by phone or visit)

Recommended Starting Doses for Opioid-Naive Patients

Morphine

Morphine remains the reference standard opioid against which all others are compared for equianalgesic dosing. It is recommended as a first-line strong opioid for cancer pain by multiple international guidelines.^{1 2}

Pharmacokinetics:

• Oral bioavailability: approximately 30% (range 15–64%, high inter-individual variability)
• Onset of action: 30–60 minutes (oral IR); 15–30 minutes (IV)
• Duration of action: 3–4 hours (oral IR); 8–12 hours (ER formulations); 2–4 hours (IV)
• Metabolism: hepatic glucuronidation to morphine-3-glucuronide (M3G, no analgesic activity, may cause neuroexcitatory effects) and morphine-6-glucuronide (M6G, potent analgesic, accumulates in renal impairment)
• Elimination: primarily renal

Cautions:

• Renal impairment: M6G accumulation can cause prolonged sedation, respiratory depression, and myoclonus; reduce dose and extend interval, or rotate to an alternative opioid (hydromorphone, fentanyl) in moderate-to-severe renal impairment (GFR below 30 mL/min)
• Histamine release: morphine can cause pruritus, flushing, bronchospasm via histamine release (non-immune mediated); more common with IV administration

Available formulations:

• Immediate-release tablets: 15 mg, 30 mg
• Oral solution: 10 mg/5 mL, 20 mg/5 mL, 100 mg/5 mL (concentrated)
• Extended-release tablets: 15 mg, 30 mg, 60 mg, 100 mg, 200 mg (every 8–12 hours)
• Extended-release capsules: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 120 mg, 130 mg, 150 mg, 200 mg (every 12–24 hours depending on formulation)
• Injectable: 1 mg/mL, 2 mg/mL, 4 mg/mL, 5 mg/mL, 8 mg/mL, 10 mg/mL, 15 mg/mL, 25 mg/mL, 50 mg/mL
• Rectal suppository: 5 mg, 10 mg, 20 mg, 30 mg

Oxycodone

Oxycodone is a semi-synthetic opioid with higher and more predictable oral bioavailability than morphine. It is considered an alternative first-line strong opioid for cancer pain.

Pharmacokinetics:

• Oral bioavailability: approximately 60–87%
• Onset of action: 15–30 minutes (oral IR)
• Duration of action: 3–6 hours (IR); 8–12 hours (ER)
• Metabolism: hepatic via CYP3A4 (primary, to noroxycodone — weakly active) and CYP2D6 (to oxymorphone — potent but minor contribution)
• Elimination: renal

Cautions:

• CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors, grapefruit juice) can increase oxycodone levels
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin) can decrease efficacy
• Moderate renal impairment: start at reduced dose (50–75% of normal); avoid or use extreme caution in severe renal impairment
• Hepatic impairment: start at reduced dose (33–50% of normal) in moderate-to-severe impairment

Available formulations:

• Immediate-release tablets: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
• Oral solution: 5 mg/5 mL, 100 mg/5 mL (concentrated)
• Extended-release tablets: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg (every 12 hours)

Hydromorphone

Hydromorphone is a semi-synthetic opioid approximately 5–7 times more potent than morphine by the oral route. It is particularly useful in patients with renal impairment (lower accumulation of active metabolites compared to morphine) and when higher potency is needed to reduce pill burden or injection volume.

Pharmacokinetics:

• Oral bioavailability: approximately 24% (range 20–50%)
• Onset of action: 15–30 minutes (oral IR); 5–15 minutes (IV)
• Duration of action: 3–4 hours (oral IR); 2–3 hours (IV)
• Metabolism: hepatic glucuronidation to hydromorphone-3-glucuronide (H3G; no analgesic activity, potential neuroexcitatory effects at very high levels in renal failure)
• Elimination: renal

Cautions:

• Severe renal impairment: H3G accumulation is possible though less clinically problematic than M6G from morphine; still requires dose adjustment
• Available in high-concentration injectable form (10 mg/mL), which is useful for subcutaneous infusions and for patients on high-dose parenteral opioids

Available formulations:

• Immediate-release tablets: 2 mg, 4 mg, 8 mg
• Oral liquid: 1 mg/mL
• Extended-release tablets: 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 32 mg (every 24 hours — only for opioid-tolerant patients)
• Injectable: 1 mg/mL, 2 mg/mL, 4 mg/mL, 10 mg/mL
• Rectal suppository: 3 mg

Fentanyl

Fentanyl is a synthetic opioid approximately 80–100 times more potent than morphine. It is highly lipophilic, enabling transdermal and transmucosal delivery. The transdermal patch is used for stable, chronic pain in opioid-tolerant patients; rapid-onset transmucosal formulations are used for breakthrough cancer pain.³

Pharmacokinetics (transdermal patch):

• Onset of action: 12–24 hours to reach therapeutic levels after first application
• Duration of action: 48–72 hours (most patients achieve 72-hour duration; some require 48-hour changes)
• Steady state: achieved after two to three patch applications (approximately 6 days)
• Metabolism: hepatic via CYP3A4 to nortentanyl (inactive)
• Elimination: renal (primarily as metabolites; less than 10% unchanged)
• After patch removal: fentanyl continues to be absorbed from the skin depot for 12–24+ hours

Cautions:

• NOT for opioid-naive patients (except possibly the lowest 12 mcg/hr patch with careful monitoring)
• Heat exposure (fever, external heat sources, heating pads) increases absorption and can cause overdose
• Cachexia/low body fat: reduced subcutaneous depot may alter absorption kinetics
• CYP3A4 inhibitors can increase fentanyl levels significantly
• Not easily titratable; dose adjustments require 48–72 hour evaluation periods
• Renal impairment: relatively safe as no significant active metabolite accumulation; preferred over morphine in severe renal failure

Available formulations:

• Transdermal patches: 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr
• Transmucosal immediate-release formulations for breakthrough pain (see breakthrough pain section below)
• Injectable: 50 mcg/mL (various volumes)

Equianalgesic Dosing Table

The equianalgesic dosing table provides approximate dose equivalencies between opioid analgesics. These ratios are derived from single-dose studies in acute pain and serve as starting points for dose calculations during opioid rotation. They should not be applied rigidly; clinical judgment and careful dose reduction for incomplete cross-tolerance are essential.⁴

Complete Equianalgesic Conversion Table

The reference standard is oral morphine 30 mg or parenteral morphine 10 mg.

Fentanyl Transdermal Patch Conversion Table

Conversion from oral morphine equivalents (total daily dose) to fentanyl transdermal patch:

Note: Some conversion tables use 60 mg oral morphine/24 hours = 25 mcg/hr fentanyl as the base ratio. The above table is conservative. When converting, clinical judgment should prevail, and conservative (lower) dosing with liberal breakthrough medication is preferred over aggressive initial dosing.

Important Conversion Caveats

1. Incomplete cross-tolerance: When rotating from one opioid to another (except fentanyl transdermal), reduce the calculated equianalgesic dose by 25–50% to account for incomplete cross-tolerance. The larger reduction (50%) should be applied when:

   • The patient is elderly or medically frail
   • The calculated equianalgesic dose is high
   • Rotating to methadone (which requires its own conversion protocol)
   • Pain is well-controlled (rotation for side effects rather than inadequate analgesia)

2. Direction of conversion matters: If rotating because of inadequate analgesia, a smaller reduction (25%) or no reduction may be appropriate, with close monitoring.

3. Methadone conversions require specific protocols and should not use this table — see the methadone section below.

4. These ratios are approximations. Published equianalgesic ratios vary across sources. Clinical monitoring during conversion is essential.

Opioid Titration

Rapid Titration for Severe Pain (Inpatient or Monitored Setting)

For opioid-naive patients with severe cancer pain (NRS 7–10 or more) requiring urgent relief:⁵

Parenteral titration protocol:

1. Administer morphine 2–5 mg IV (or hydromorphone 0.2–0.5 mg IV, or equivalent) over 1–2 minutes
2. Reassess pain and sedation in 15 minutes
3. If pain remains severe and patient is alert (sedation score less than 2 on a 0–3 scale): repeat the same dose
4. Continue reassessing and re-dosing every 15–30 minutes until pain is reduced to tolerable levels or dose-limiting side effects occur
5. Once pain is controlled, calculate the total amount of opioid given in the titration period
6. Convert to a scheduled regimen: divide the total titration dose over the appropriate dosing interval

Oral titration protocol for moderate-to-severe pain:

1. Administer morphine IR 5–15 mg orally (or oxycodone IR 5–10 mg, or hydromorphone IR 2–4 mg)
2. Reassess pain in 60 minutes
3. If pain remains above goal: administer another dose of the same magnitude
4. Continue reassessing and re-dosing every 60 minutes until adequate pain relief
5. Once the effective single dose is identified, schedule it every 4 hours (morphine, hydromorphone) or every 4–6 hours (oxycodone)

Gradual Titration (Outpatient)

For outpatient titration of opioids in patients with moderate pain or less urgent situations:

1. Start with a scheduled IR opioid at the recommended starting dose (see table above)
2. Prescribe a breakthrough dose of 10–15% of the total daily opioid dose as an IR formulation, available every 1–2 hours as needed
3. Instruct the patient to keep a pain diary recording: pain scores, scheduled medication times and doses, breakthrough medication times and doses, side effects
4. Reassess by phone or visit in 24–72 hours
5. If more than 3–4 breakthrough doses are needed per day, increase the scheduled dose:
   • Calculate total 24-hour opioid consumption (scheduled + breakthrough)
   • Redistribute as the new scheduled dose
   • Recalculate the new breakthrough dose (10–15% of the new total daily dose)
6. When a stable daily dose is established (48–72 hours of consistent dosing), consider conversion to an ER formulation with continued IR breakthrough dosing

Dose Adjustment Guidelines

Breakthrough Pain Management

Definition and Classification

Breakthrough cancer pain (BTcP) is defined as a transient exacerbation of pain occurring against a background of otherwise adequately controlled baseline pain. It occurs in 40–80% of cancer patients with chronic pain and is associated with significant functional impairment and psychological distress.⁶

Types of breakthrough pain:

Breakthrough Dose Calculation

The standard breakthrough (rescue) dose is 10–15% of the total 24-hour oral morphine equivalent dose, administered as an IR opioid formulation.¹

Breakthrough doses may be repeated every 1–2 hours as needed for oral formulations (every 15–30 minutes for parenteral formulations). If more than 3–4 breakthrough doses are required per day on a consistent basis, the around-the-clock dose should be increased.

Rapid-Onset Opioids for Breakthrough Pain

Transmucosal immediate-release fentanyl (TIRF) products are specifically designed for breakthrough cancer pain in opioid-tolerant patients. They provide onset of analgesia within 5–15 minutes (compared to 30–60 minutes for oral IR opioids). These formulations must be individually dose-titrated and should NOT be dosed based on the patient’s around-the-clock opioid dose — there is no reliable conversion between the around-the-clock dose and the effective TIRF dose.⁷

Critical safety points for TIRF products:

• Restricted access programs exist in many jurisdictions
• Only for opioid-tolerant patients (receiving at least 60 mg oral morphine equivalents/day for at least one week)
• Must be individually titrated starting at the lowest dose; do not convert from the background opioid dose
• TIRF products are NOT interchangeable — each formulation has unique pharmacokinetics and requires separate titration
• Patients must be educated on proper administration technique for each formulation

Extended-Release Opioid Formulations

Once a stable daily opioid requirement has been established through titration with IR formulations (typically over 48–72 hours), conversion to an ER formulation is appropriate for patients with persistent pain requiring around-the-clock analgesia.

Conversion from IR to ER

1. Calculate the total daily dose of the IR opioid
2. Divide into the ER dosing schedule:
   • Twice-daily ER morphine or oxycodone: divide total daily dose by 2
   • Once-daily ER morphine or hydromorphone: use total daily dose as the single daily dose
   • Fentanyl transdermal: use the conversion table above
3. Continue to prescribe IR breakthrough doses (10–15% of total daily dose)
4. Administer the first ER dose concurrently with or shortly before the last scheduled IR dose would have been due

ER Formulation Overview

Opioid Rotation

Indications for Opioid Rotation

Opioid rotation (switching from one opioid to another) should be considered when:⁸

• Intolerable side effects persist despite appropriate management (e.g., refractory constipation, nausea, sedation, myoclonus, cognitive impairment, pruritus)
• Inadequate analgesia despite dose escalation to the point of dose-limiting side effects
• Change in clinical situation requires a different route of administration
• Development of suspected opioid-induced hyperalgesia (worsening diffuse pain with opioid dose escalation, allodynia)
• Drug interactions with the current opioid
• Patient preference or formulary considerations
• Renal or hepatic function change requiring a different opioid

Opioid Rotation Procedure

Step 1: Calculate the total current 24-hour opioid dose

Step 2: Convert to the oral morphine equivalent daily dose (MEDD) using the equianalgesic table

Step 3: Convert from MEDD to the new opioid using the equianalgesic table

Step 4: Apply an incomplete cross-tolerance reduction of 25–50%:

• 25% reduction: if rotating due to inadequate analgesia (the patient needs at least the equianalgesic dose)
• 50% reduction: if pain is well-controlled and rotation is for side effects, or if the patient is elderly/frail, or if the calculated equianalgesic dose is high

Step 5: For the fentanyl transdermal patch, use the conversion table directly; cross-tolerance reduction is built into conservative conversion tables

Step 6: Calculate the new breakthrough dose (10–15% of total daily dose of the new opioid, as an IR formulation)

Step 7: Reassess within 24–72 hours and titrate as needed

Worked Example

A patient on oxycodone ER 40 mg every 12 hours (total 80 mg/day oral oxycodone) has intolerable nausea. Rotation to hydromorphone is planned.

1. Total daily oxycodone: 80 mg oral
2. Convert to MEDD: 80 mg oxycodone x (30 mg morphine / 20 mg oxycodone) = 120 mg oral morphine equivalent/day
3. Convert MEDD to hydromorphone: 120 mg morphine x (6 mg hydromorphone / 30 mg morphine) = 24 mg oral hydromorphone/day
4. Apply 25–50% reduction for incomplete cross-tolerance (rotation for side effects, so use 50% reduction): 24 mg x 0.50 = 12 mg oral hydromorphone/day
5. Prescribe: hydromorphone ER 12 mg once daily, OR hydromorphone IR 2 mg every 4 hours (total 12 mg/day)
6. Breakthrough: 10–15% of 12 mg = 1.2–1.8 mg; prescribe hydromorphone IR 2 mg every 2 hours as needed
7. Reassess in 24–48 hours and titrate upward if needed

Methadone

Methadone is a unique opioid with properties that make it valuable for complex cancer pain but also potentially dangerous if not used by knowledgeable prescribers. Its use should be initiated or closely supervised by clinicians experienced with its pharmacology.⁹

Unique Pharmacological Properties

QTc Monitoring Protocol

Methadone Dosing: Initiation in Opioid-Naive Patients

Methadone Conversion from Other Opioids

Methadone conversion is NOT linear. The equianalgesic ratio of morphine to methadone increases with higher morphine doses, meaning methadone becomes relatively more potent at higher dose ranges. Multiple conversion methods exist; the most widely used are presented below.

Method 1: Ayonrinde Conversion Table (Widely Used in Palliative Care)

After calculating the estimated methadone daily dose, apply an additional 25–50% reduction and divide into 3 doses (every 8 hours). Use an IR opioid (not methadone) for breakthrough pain during the conversion period.

Method 2: Rapid Switch (Stop-and-Go)

1. Discontinue the current opioid
2. Start methadone at the calculated dose (using the table above with 25–50% reduction)
3. Prescribe a short-acting opioid (not methadone) for breakthrough pain
4. Monitor closely for 5–7 days (the accumulation period)
5. Titrate methadone dose cautiously after day 5–7

Method 3: Gradual Rotation (3-Day Switch)

1. Day 1: Reduce the current opioid by one-third; replace with one-third of the calculated methadone dose
2. Day 2: Reduce the current opioid by another third; increase methadone to two-thirds of the calculated dose
3. Day 3: Discontinue the current opioid; give the full calculated methadone dose
4. Monitor for accumulation over the following 5–7 days
5. Provide a short-acting opioid for breakthrough pain throughout

Common Drug Interactions with Methadone

Opioid Adverse Effect Management

Opioid adverse effects are common, expected, and generally manageable with proactive prevention and treatment. Failure to address side effects is a major contributor to patient non-adherence and inadequate pain control. Anticipatory management should begin at the time of opioid initiation.¹⁰

Constipation

Opioid-induced constipation (OIC) affects 40–90% of patients on chronic opioid therapy. Unlike most opioid side effects, tolerance does NOT develop to constipation.

Prevention (mandatory for all patients starting opioids):

• Start a prophylactic bowel regimen simultaneously with opioid initiation
• Dietary measures (fluid intake, fiber) are helpful but insufficient alone

Stepwise Management:

Key principle: Do NOT use bulk-forming laxatives (psyllium, methylcellulose) for OIC — they can worsen obstruction in the setting of opioid-reduced motility without adequate fluid intake.

Nausea and Vomiting

Opioid-induced nausea affects 15–40% of patients. Unlike constipation, tolerance usually develops within 3–7 days.

Management approach:

1. Warn patients nausea often improves within 3–7 days
2. Prescribe an antiemetic for the first 5–7 days of opioid therapy
3. If nausea persists beyond 1–2 weeks, consider opioid rotation
4. Rule out other causes (constipation, chemotherapy, brain metastases, hypercalcemia)

Sedation and Cognitive Impairment

Sedation is common during opioid initiation and dose escalation. Tolerance typically develops within 3–7 days. Persistent sedation may indicate over-dosing or drug accumulation.

Management:

1. Reassess opioid dose; reduce if pain is well-controlled
2. Eliminate unnecessary sedating co-medications (benzodiazepines, antihistamines, muscle relaxants)
3. If sedation persists despite dose optimization:
   • Methylphenidate 5 mg orally each morning and noon (maximum 20 mg twice daily); avoid late-day dosing to prevent insomnia
   • Modafinil 100–200 mg orally each morning (alternative)
4. Consider opioid rotation (some opioids may cause less sedation in individual patients)

Respiratory Depression

Clinically significant respiratory depression is rare in cancer patients who are on stable opioid doses, as pain is a physiological antagonist to respiratory depression and tolerance develops with chronic use. Risk is highest with opioid initiation, rapid dose escalation, addition of other CNS depressants, and in the setting of renal or hepatic impairment causing drug accumulation.

Risk factors in cancer patients:

• Opioid-naive status with rapid titration
• Concurrent benzodiazepines, gabapentinoids, or other sedating medications
• Renal impairment (morphine M6G accumulation)
• Hepatic impairment
• Sleep-disordered breathing / obstructive sleep apnea
• Elderly, cachectic, or debilitated patients
• Methadone accumulation during first 5–7 days

Management of opioid-induced respiratory depression:

Naloxone protocol for opioid-induced respiratory depression in opioid-dependent cancer patients:

In cancer patients on chronic opioids, naloxone must be used cautiously to avoid precipitating acute withdrawal and severe pain crisis.

1. Dilute naloxone 0.4 mg (1 mL of 0.4 mg/mL solution) in 9 mL normal saline to create a concentration of 0.04 mg/mL
2. Administer 1–2 mL (0.04–0.08 mg) IV every 2–3 minutes
3. Goal: restore adequate respirations (rate above 8–10/min) WITHOUT fully reversing analgesia
4. Duration of naloxone action is 30–90 minutes — shorter than most opioids; repeat dosing or continuous infusion may be needed
5. Monitor for at least 2 hours after the last naloxone dose; longer monitoring if a long-acting opioid was the cause

Pruritus

Opioid-induced pruritus (most common with morphine due to histamine release) affects 2–10% of patients on systemic opioids and is more frequent with neuraxial (epidural/intrathecal) administration.

Management:

• Antihistamines: diphenhydramine 25–50 mg every 6–8 hours (sedating) or cetirizine/loratadine (non-sedating) — efficacy is variable
• Opioid rotation to a non-morphine opioid (hydromorphone, fentanyl, oxycodone — lower histamine release)
• For neuraxial opioid-induced pruritus: nalbuphine 2.5–5 mg IV, or low-dose naloxone infusion (0.25–1 mcg/kg/hr IV)
• Ondansetron 4–8 mg IV for neuraxial opioid pruritus (case series evidence)

Myoclonus

Opioid-induced myoclonus (involuntary jerking movements) can occur with high-dose opioids or in the setting of renal impairment (accumulation of metabolites, particularly M3G from morphine).

Management:

1. Opioid rotation (first-line treatment for significant myoclonus)
2. Dose reduction if pain control permits
3. Clonazepam 0.5–1 mg orally twice daily (if myoclonus is mild and opioid rotation is not feasible)
4. Baclofen 5–10 mg orally three times daily (alternative)
5. Correct dehydration and renal impairment if present

Opioid Tapering and Discontinuation

When cancer pain resolves or significantly improves (e.g., after successful anticancer treatment, radiation, or interventional procedure), opioid de-escalation should be undertaken gradually to avoid withdrawal symptoms.

General taper protocol:

• Reduce total daily dose by 10–25% every 2–3 days initially
• Once at 30% of original dose, slow the taper to 10% reductions every 5–7 days
• If withdrawal symptoms occur (anxiety, diaphoresis, tachycardia, diarrhea, goosebumps, muscle aches), hold the taper and stabilize at current dose before resuming
• Total taper duration: typically 1–4 weeks for short-term opioid use; may require weeks to months for long-term use

References